Concomitant treatment with nonsteroidal anti-inflammatory drugs and vitamin K antagonists: critical appraisal of the recommendations issued by the French Agency for Healthcare Product Safety.
Bannwarth
B
B
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003257:Consumer Product Safety / Q000331:legislation & jurisprudence; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004335:Drug and Narcotic Control; D005602:France; D006077:Government Agencies; D006287:Health Planning Guidelines; D006801:Humans; D012216:Rheumatic Diseases / Q000188:drug therapy*; D014812:Vitamin K / Q000037:antagonists & inhibitors*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000925:Anticoagulants; D018501:Antirheumatic Agents; D014812:Vitamin K